



## Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users

Journal:	<i>Journal of Viral Hepatitis</i>
Manuscript ID	JVH-00061-2017
Manuscript Type:	Commissioned Review
Date Submitted by the Author:	30-Jan-2017
Complete List of Authors:	Shawa, Isaac; Plymouth University, Peninsula Schools of Medicine and Dentistry, Institute of Translational & Stratified Medicine, Hepatology Research Group Felmlee, Daniel; Plymouth University Peninsula Schools of Medicine & Dentistry, Institute of Translational & Stratified Medicine, Hepatology Research Group Hegazy, Doha; Plymouth University Peninsula Schools of Medicine & Dentistry, Institute of Translational & Stratified Medicine, Hepatology Research Group Sheridan, David; Plymouth University Peninsula Schools of Medicine & Dentistry, Institute of Translational & Stratified Medicine Cramp, Matthew; Peninsula College of Medicine & Dentistry, Institute of Translational & Stratified Medicine, Hepatology Research Group
Keywords:	Cytokines, Exposed uninfected (EU), Hepatitis C virus (HCV), Immune response, people who inject drugs (PWID)

1  
2  
3 TITLE PAGE  
4

5  
6 **Running title:** HCV mechanisms of resistance  
7  
8

9  
10  
11  
12 **Title:** ‘Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug  
13 users’  
14  
15

16  
17  
18  
19  
20  
21 **Authors:**  
22

23  
24 Isaac Thom Shawa, Daniel J Felmlee, Doha Hegazy, David A Sheridan, Matthew E Cramp  
25  
26

27  
28 **Address:**  
29

30  
31 Institute of Translational & Stratified Medicine, Hepatology Research Group  
32

33  
34 Plymouth University Peninsula Schools of Medicine & Dentistry  
35

36  
37 Plymouth, PL6 8BU  
38

39  
40 United Kingdom  
41  
42

43  
44  
45  
46  
47 **Corresponding author:**  
48

49  
50 **Prof. Matthew Cramp** ([matthew.cramp@nhs.net](mailto:matthew.cramp@nhs.net))  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

A rare outcome following exposure to hepatitis C virus (HCV) is a lack of observable infection as clinically measured by HCV RNA or HCV recognising antibodies. The population who exhibit this trait is termed exposed uninfected (EU). Increasing evidence has refined characterisation of these individuals, distinct from those who become infected but spontaneously clear HCV. Study of the EU population is highly pertinent for the discovery of antiviral mechanisms of resistance that can reveal antiviral therapeutic strategies.

This review provides an overview of similarities and differences of the EU population relative to spontaneous resolvers and the majority whom develop chronic HCV infection, and focusses on possible mechanisms of resistance including innate and adaptive immunity, genetics and lipid interactions.

**Key words:**

Cytokines; Exposed uninfected (EU); Hepatitis C virus (HCV); Immune response; Liver; people who inject drugs (PWID); Resistance

**Word count: 3084**

## Introduction

Hepatitis C virus (HCV) infection is (1) a major global public health problem that can result in cirrhosis, liver cancer and death with estimates of prevalence of antibodies against HCV (anti-HCV) ranging between 1.3 – 2.1 % (2). Injection drug use is the dominant risk factor for HCV transmission in economically developed countries. Longer duration of injecting drug use is associated with increased prevalence of HCV infection (64 – 94% HCV anti-HCV positive) (3,4). Epidemiological data indicates that globally 60 – 80% of people who inject drugs (PWIDs) are anti-HCV positive, with over 80% prevalence in 12 countries (5). This equates to approximately 10 million PWIDs who are anti-HCV positive worldwide, with an estimated 1.6 million in China, 1.5 million in the United States of America, and 1.3 million in Russia (5).

There is evidence that a small proportion of PWIDs remain HCV RNA and anti-HCV negative despite their history of repeated exposure to HCV through sharing of injecting needles and other paraphernalia. Our group and others have previously characterised this cohort of PWIDs defining them as ‘exposed uninfected’ (EU) (6–10). The phenotype of repeated exposure to HCV without the development of infection is of considerable interest because it suggests these individuals are in some way resistant to HCV infection. This review considers the phenotypic definitions of the EU cohort, and the distinct immunological and genetic features that characterise the EU group to gain insights into possible mechanisms of HCV resistance.

## Differences between HCV Exposed Uninfected (EU), Spontaneous Resolvers (SR) and those with chronic HCV (CHCV)

Parenteral HCV exposure results in one of 3 different outcomes: the majority of individuals develop chronic HCV infection (CHCV) with detectable anti-HCV and persisting HCV RNA, while approximately 20% of people spontaneously resolve infection (SR) (11) with detectable anti-HCV but clearance of HCV RNA, and finally a minority, who despite similar viral exposure, remain uninfected (EU) lacking detectable anti-HCV and HCV RNA. These 3 outcomes can be characterised by differing immunological and genetic profiles (Table 1).

### HCV 'exposed uninfected' designation

HCV exposure without infection has been described by several groups. While we have termed this cohort 'exposed uninfected' (6), other groups describe a similar phenomenon in both HCV and Human immunodeficiency virus (HIV) as 'highly exposed seronegative (HESN)' (12), 'highly exposed persistently seronegative (13), repeatedly 'exposed seronegative (ESN)' (14). For meaningful debate and understanding, there needs to be clarity about phenotypic nomenclature.

### Exposed uninfected individuals represent a distinct group

In the absence of serological evidence for developing infection, HCV exposure can only be determined by probability based on the history of risk behaviour. It is known that PWIDs who share needles or other injecting paraphernalia with individuals known to have HCV infection are at high risk of HCV exposure and that HCV sero-prevalence increases with duration of injection history (15,16) as the cumulative probability of actual exposure increases.

The EU group therefore needs to be carefully distinguished from *unexposed* naïve cases by close scrutiny of the probability of actual HCV exposure. EU groups are practically defined as individuals whose test results are serially negative for anti-HCV and HCV RNA on at least 2 occasions, more than

1  
2  
3 6 months apart, in the context of ongoing high risk of HCV exposure, typically through injection drug  
4 use and sharing of injection paraphernalia (7,17). The probability of true HCV exposure has mostly  
5 been determined on the basis of risk questionnaires. An example utilising exceptional high-risk  
6 behaviours was described by Sugden et al, using a composite risk index for HCV exposure based on a  
7 time dependent cox-regression analysis of 14 separate weighted risk factors of risk behaviours and  
8 demographics (18). Significantly higher composite risk scores were found in those that subsequently  
9 became infected. However, within the uninfected group there were individuals that remained  
10 uninfected despite high risk behavioural profiles. Separation of the uninfected group's risk into  
11 tertiles (two points that divide data into three equal parts) indicated that those in the highest tertile  
12 had a pattern of risk actually higher than that observed in subjects who subsequently become  
13 infected (18). Thus based on statistical models it is highly probable that these subjects had been  
14 exposed to HCV but despite this remained uninfected.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 An alternative definition of HCV exposure in EUs is the presence of HCV specific immunological  
31 responses (18) in the absence of anti-HCV or HCV RNA. T cell responses can be measured to arrays of  
32 HCV peptides spanning structural and non-structural (NS) viral proteins, and are a marker of  
33 immunological exposure to HCV. ELISpot is a technique employed for detection and analysis of  
34 individual cells that secrete cytokines in response to in-vitro stimulation with specific antigens (in  
35 this case HCV peptides)(19) and is highly sensitive allowing for detection of as few as one cell in  
36 100,000 (20). Cellular IFN- $\gamma$  production is used as a readout of single cell activation with individual  
37 spots representing each cytokine secreting cell (20). Using ELISpot up to 60% of high risk individuals  
38 have detectable HCV-specific T cell responses (6).  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 Both definitions of HCV exposure have their flaws, with risk stratification according to injection  
51 history dependent on self-reported behaviours, and immunological definition potentially excluding  
52 cases who have alternative pathways of resistance and who don't mount a T cell response despite  
53 viral exposure. Despite these limitations it is clear that in some individuals repeated parenteral  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 exposure to HCV through drug use does not result in infection becoming established and defining  
4  
5 mechanisms of resistance in these cases is a key question for HCV research.  
6  
7  
8  
9

## 10 11 **Immunological resistance to HCV**

12  
13  
14  
15 Given the high prevalence of T cell responses in the EU cohort, immunological mechanisms may be  
16  
17 an important component of HCV resistance and the data suggesting differences in adaptive and  
18  
19 innate immune responsiveness in EU compared to others is reviewed here.  
20  
21

### 22 **a) adaptive immune responses**

#### 23 **i. T Cells**

24  
25  
26  
27  
28 Spontaneous resolution of HCV infection is associated with robust T cell responses (21,22)  
29  
30 and early, vigorous and multi-specific T cell responses targeting multiple viral epitopes  
31  
32 appear crucial for spontaneous clearance (reviewed in (23)). Conversely, an ineffective early  
33  
34 cell-mediated response may result in the development of chronic HCV infection (24). In SRs  
35  
36 viral clearance is dependent on a complex set of viral-host interactions such as young age  
37  
38 (25); females respond better than males (26), host immune response and genetics,  
39  
40 neutralising antibodies, and viral specific factors that include genotypes, and diversity of  
41  
42 quasispecies (27).  
43  
44  
45

46  
47 Partial protective immunity after spontaneous resolution of HCV infection has been reported,  
48  
49 with lower rates of HCV reinfection than would be expected in a matched uninfected  
50  
51 population (28). Detectable HCV-specific T cell responses remain for many years after  
52  
53 spontaneous clearance (29) but their role in providing this partial protection has not been  
54  
55 established.  
56  
57  
58  
59  
60

1  
2  
3 In exposed uninfected cases up to 60% have demonstrable T cell responses (6), often to  
4  
5 multiple viral antigens, but these responses are typically much weaker than those seen in SR  
6  
7 (7,8,17). Furthermore these T cell responses wane rapidly on cessation of injection drug use,  
8  
9 and seem to require continued HCV exposure as a consequence of ongoing injection drug use  
10  
11 to be maintained (30). HCV specific cytotoxic T cell responses have been reported in  
12  
13 imprisoned PWIDs in association with transient hepatitis C viraemia that cleared without  
14  
15 seroconversion (reviewed in (31)). Similar HCV-specific T cell immune responses have been  
16  
17 described in aviraemic and seronegative family members of HCV infected individuals (32,33)  
18  
19 and in healthcare workers following needle stick exposure to HCV with evidence of an early  
20  
21 T cell response induced in the absence of detectable anti-HCV or HCV RNA (34). Overall  
22  
23 these studies suggest that low dose exposure to HCV can prime HCV specific T cells and that  
24  
25 repeated exposure can maintain that response (32,33,35) so that the frequency and dose of  
26  
27 HCV exposure may influence any resulting degree of protection.  
28  
29  
30  
31

32 The degree to which T cell responses confer protection in EUs is controversial. A nested case  
33  
34 control series from a prospectively studied cohort of PWIDs in Australia revealed no  
35  
36 differences in T cell responses assessed by HCV-specific IFN- $\gamma$  ELISpot, and HCV-specific CD4 T  
37  
38 effector responses between those who developed incident HCV infection compared to those  
39  
40 who remained uninfected (EU) suggesting that whilst HCV-specific cellular immunity is  
41  
42 prevalent in EU subjects it did not correlate with protection in their cohort (36).  
43  
44  
45

46 In keeping with this lack of correlation between demonstrable T cell responses and  
47  
48 protection from HCV infection, other studies have shown clearance of low levels of HCV  
49  
50 viraemia without developing anti-HCV antibodies can occur in the absence of any  
51  
52 demonstrable T cell immune responses (37,38).  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 In conclusion, whilst HCV-specific T cell immunological responses do provide good evidence  
4 of viral exposure, their role in conferring any protection from infection remains unproven,  
5  
6 which suggests that there are other mechanisms involved in resistance to HCV infection.  
7  
8  
9

10 **ii. B cells and anti-HCV mediated protection**

11  
12  
13  
14 There is growing evidence that a robust anti-envelope antibody response can contribute  
15 significantly to viral clearance in acute infection (39) with the rapid onset of anti-HCV capable  
16 of neutralizing diverse strains of HCV being associated with clearance (40). Furthermore, in  
17  
18 vitro and in vivo studies have suggested that broadly neutralizing antibodies may contribute  
19 to resolution of infection even once HCV has become established (41,42). Studies in  
20 chimpanzees utilising HCV neutralizing antibodies have indicated that viral replication can be  
21 delayed after challenging chimpanzees with pre-existing anti-HCV (43). Robust neutralising  
22 antibody responses not identified by conventional HCV antibody assays may therefore  
23 contribute to HCV resistance in EUs. We recently reported on finding significant IgG  
24 reactivity to HCV envelope proteins in 20 of 42 HCV antibody and HCV RNA negative EU cases,  
25 with 6 of them showing evidence of a significant virus neutralizing effect (44). IgG from the  
26 neutralizing samples did not compete for binding sites with several well-characterized  
27 antibodies to known conformational epitopes on the E2 glycoprotein, suggesting novel  
28 epitopes may be targeted (44). This is the only report to date of HCV-specific humoral  
29 immune responses in exposed uninfected injection drug users. Current work seeks to  
30 identify if humoral responses correlate with the presence of T cell responses. The presence  
31 of specific anti-envelope antibodies provides further confirmation of HCV exposure in these  
32 cases and is a plausible, but as yet unproven, mechanism by which some of these subjects  
33 may have resisted HCV infection following a low dose inoculation.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**b) Innate immunity**

The innate immune system is the first line of defence against viral illness with the potential to prevent infection as well as facilitate subsequent adaptive immune responses and modify outcome of established infection. Natural killer (NK) cells are considered the principal innate effectors and when activated can kill either directly via the release of granzyme and perforin containing cytotoxic granules or via cytokines such as IFN- $\gamma$ . NK cells also act indirectly by influencing the activation and/or trafficking of other key immune cell populations, including T cells, to promote adaptive immune responses.

Natural Killer cells are highly enriched in the liver in comparison to peripheral blood (45). NK cell activation is tightly controlled through a complex balance of activating and inhibitory receptors, with inhibitory NK receptors (NKR) in steady-state conditions dominating signals from activating receptors, to safeguard from NK cell reactivity toward normal, healthy cells. The main classes of NKR are the predominantly inhibitory killer immunoglobulin-like receptors (KIR), the natural killer group 2 (NKG2) family of inhibitory (NKG2A) and activatory (NKG2C/D) isoforms, and the activating natural cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46.

There is increasing evidence to support a key role for innate immune responses in EU cases. A study looking at serum cytokine profiles in EU cases found significantly elevated levels of the pro-inflammatory innate immune cytokine interleukin-6 and chemokine interleukin-8 in EU's compared to those with chronic HCV, spontaneous resolvers or healthy controls (46). A genetic study of the NK cell KIR receptors identified homozygosity for KIR2DL3:HLA-C1, which is linked to a readily activated NK cell phenotype (47), to be associated with the resistance to HCV infection seen in EU cases (48). Of interest, the IL28B variant strongly associated with spontaneous resolution of HCV infection and a favourable treatment outcome was not found to be associated with these EU cases indicating that EU individuals are a distinct population from patients who spontaneously resolve HCV infection (48).

1  
2  
3 More recently studies have reported phenotypic and functional differences in NK cells in high-  
4 risk cohorts that do not develop HCV infection. In the first HCV seronegative PWIDs were shown  
5 to have increased levels of KIR2DL3<sup>+</sup>NKG2A<sup>-</sup> NK cells compared to PWIDs with chronic or  
6 resolved HCV infection and these cells were not susceptible to HLA-E mediated inhibition (49).  
7  
8 The strongest evidence to date comes from a prospectively studied cohort of seronegative  
9 PWIDs in Australia (36). This nested case-control series studied 28 previously seronegative cases  
10 who seroconverted (incident cases of HCV) matched by demographics and risk behaviour to 28  
11 EU subjects who remained seronegative on follow up. Samples were assayed for NK cell  
12 phenotypes and function before and after incident HCV infection to seek correlates with ongoing  
13 resistance to HCV in those who remained uninfected. Sustained NK cell activation was found to  
14 contribute to protection against HCV infection with significantly higher numbers of both  
15 activated and cytotoxic cells found in the EU subjects together with higher frequencies of  
16 interferon gamma (IFN- $\gamma$ ) producing NK cells. In contrast, no correlation with HCV-specific T cell  
17 responses and ongoing protection was identified.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 c) Other possible mechanisms of HCV resistance

#### 40 i. Genetic

41  
42 To date genetic studies in EU cases have been limited by the relatively small cohorts identified  
43 and reported on, so that studies have focussed on specific candidate genes. Further  
44 collaborative investigations combining different EU cohorts will be needed to undertake any  
45 appropriately powered genome wide association study. Candidate genes include those that  
46 influence the host innate/and or adaptive immune responses as well as those encoding HCV  
47 receptor molecules.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 We have previously shown an association between the variant IL-12B C allele and resistance to  
4 HCV infection in EU cases (50). This variant is associated with higher IL-12 production (51) and  
5  
6 thus may be of relevance in promoting effective anti-viral immune responses. As described in  
7  
8 the section on innate immune responses, a study on the genetics of NK cell KIR receptors  
9  
10 identified a variant associated with a readily activated NK cell phenotype (KIR2DL3:C1  
11  
12 homozygotes) (47), to be associated with the resistance to HCV infection seen in EU cases (48).  
13  
14

15  
16  
17 HCV entry into hepatocytes is a complex multi-step process that involves a number of host  
18  
19 factors and co-receptors including CD81, Scavenger receptor class B member 1 (SRB1), the tight  
20  
21 junction proteins claudin 1, 6 and 9 and occludin as well as epidermal growth factor receptor  
22  
23 (EGFR), Ephrin receptor A2 (EphA2), transferrin receptor 1 (TfR1), Niemann-Pick C1-like 1  
24  
25 (NPC1L1) and others (reviewed in (52)).  
26  
27

28  
29 CD81 appears to be very highly conserved with no genetic alterations found in a study of EU  
30  
31 cases, HCV infected cases and controls (53). Studies reported on a French cohort of HIV infected  
32  
33 PWIDs with and without HCV infection (the HCV negative cases were considered EU) looked at  
34  
35 sequencing findings in 22 EU cases and found no alteration in Claudin-1 (54), but did find  
36  
37 heterozygous variants in claudin-6 and occludin in one case and two heterozygous variants in  
38  
39 SRB-1 in another (55). The relevance of these to resistance to HCV is unclear as detailed study  
40  
41 showed that the variations in Claudin-6 and occludin identified did not confer resistance to HCV  
42  
43 infection in an in-vitro model (56).  
44  
45  
46  
47  
48  
49

#### 50 51 **ii) Lipids and HCV resistance**

52

53  
54 HCV interacts with host lipid metabolism at all stages of the viral lifecycle - from attachment and  
55  
56 entry into hepatocytes, to replication and assembly of new viral particles. Circulating HCV is  
57  
58  
59  
60

1  
2  
3 associated with lipoproteins as complex 'lipoviral particles' (LVP) (57) which contain viral RNA, viral  
4  
5 proteins, and host apolipoprotein constituents including apoB, apoE, apoA1, and apoC (58). Growing  
6  
7 evidence suggests that the LVP lipid and apolipoprotein components facilitate viral attachment to  
8  
9 host cells by binding to cellular lipoprotein receptors and that the exchangeable apoE appears to be  
10  
11 crucial for infectivity at the attachment step and at masking envelope glycoproteins from neutralising  
12  
13 antibodies (59). HCV replication takes place on lipid droplets with co-localization of core protein and  
14  
15 non-structural NS5A to the lipid droplet. Production of infectious HCV is dependent on hepatocyte  
16  
17 machinery for the export of very low density lipoproteins (VLDL) (60).

20  
21 Thus evidence points toward a key role for lipid metabolism in the HCV lifecycle, and the close  
22  
23 association with lipids and lipoproteins contributes to HCVs ability to evade the host's immune  
24  
25 surveillance. Given this co-dependency on host lipid pathways, it is plausible that any mechanism  
26  
27 that would disrupt the LVP formation would potentially reduce the viral infectivity and influence  
28  
29 outcome following HCV exposure.

32  
33 Recently reported, but preliminary, data using lipidomics profiling demonstrated that the HCV  
34  
35 resistant EU phenotype was clearly distinct from HCV susceptible individuals (61). The role of lipids  
36  
37 and lipid pathways in conferring HCV resistance is of interest but remains to be clarified.

38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conclusion

HCV exposure through injection drug use that does not result in infection is now well described in several countries. This EU group exhibit resistance to HCV infection. Detailed study to date suggests that this resistance is associated with an increased likelihood of having adaptive HCV-specific T and B cell responses, and an upregulated innate immune response. Although the role these HCV-specific responses in conferring resistance to HCV infection remains ambiguous, detection of these responses confirms exposure in the absence of anti-HCV immunoglobulin or HCV RNA. Possible mechanisms of resistance include upregulated innate immune responses including cytokine production, genetic variation, and altered lipid composition. Current evidence suggests that the EU phenotype represents a spectrum, with varying degrees of resistance to HCV, possibly involving complex interactions between the inoculation size and frequency of HCV exposure with immune mediated pathways and other host factors such as genetic polymorphisms.

The accurate characterisation of HCV exposed uninfected cases remains crucial to future studies and raises issues regarding the definition and confirmation of HCV exposure. There remains a need for a universally agreed definition of exposure on the basis of probability derived from risk behaviours and duration of drug use, and / or evidence of immune responsiveness to HCV antigens, in order to define robust exposed uninfected cohorts to investigate pathways of HCV resistance. A collaborative effort between groups using agreed definitions for EU cases could provide sufficient case numbers to undertake appropriately powered genetic studies. A better understanding of all the factors associated with HCV resistance would be a major step forward in our understanding of the pathogenesis of this highly prevalent infection and in the search for alternative therapeutic strategies.

**Acknowledgement and Disclosures**

None to declare

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

**References**

1. European Association for Study of Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Vol. 60, Journal of Hepatology. 2014.
2. Gower E, Estes C C, Hindman S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol. European Association for the Study of the Liver; 2014;61(1):S45–57.
3. Diaz T, Des Jarlais DC, Vlahov D, Perlis TE, Edwards V, Friedman SR, et al. Factors associated with prevalent hepatitis C: Differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health. 2001;91(1):23–30.
4. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore). 1995;74:212–20.
5. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet. Elsevier Ltd; 2011;378(9791):571–83.
6. Thuraiajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, et al. Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis. 2008 Dec 15;198(12):1749–55.
7. Mizukoshi E, Eisenbach C, Edlin BR, Newton KP, Raghuraman S, Weiler-Normann C, et al. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis. 2008;198(2):203–12.
8. Zeremski M, Shu M a., Brown Q, Wu Y, Des Jarlais DC, Busch MP, et al. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat. 2009;16:10–20.
9. Freeman AJ, Ffrench R a, Post JJ, Harvey CE, Gilmour SJ, White P a, et al. Prevalence of



- 1  
2  
3 production of virus-specific interferon-gamma among seronegative hepatitis C-resistant  
4  
5 subjects reporting injection drug use. *J Infect Dis.* 2004;190(6):1093–7.  
6  
7  
8 10. Golden-Mason L, Cox AL, Randall J a., Cheng L, Rosen HR. Increased natural killer cell  
9  
10 cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk  
11  
12 individuals and inhibits replication in vitro. *Hepatology.* 2010;52:1581–9.  
13  
14  
15 11. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and  
16  
17 spontaneous clearance of hepatitis C virus. *Nature.* Nature Publishing Group;  
18  
19 2009;461(7265):798–801.  
20  
21  
22 12. Horton RE, McLaren PJ, Fowke K, Kimani J, Ball TB. Cohorts for the study of HIV-1-exposed but  
23  
24 uninfected individuals: benefits and limitations. *J Infect Dis.* 2010;202 Suppl(Suppl 3):S377–81.  
25  
26  
27 13. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, et al. Mucosal and plasma IgA  
28  
29 from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. *AIDS.*  
30  
31 2000;14(13):1917–20.  
32  
33  
34 14. Clerici M, Giorgi J V, Chou CC, Gudeman VK, Zack JA, Gupta P, et al. Cell-mediated immune  
35  
36 response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men  
37  
38 with recent sexual exposure to HIV-1. *J Infect Dis.* 1992;165(6):1012–9.  
39  
40  
41 15. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, et al. Modelling hepatitis C virus  
42  
43 incidence, prevalence and long-term sequelae in Australia, 2001. *Int J Epidemiol.*  
44  
45 2003;32(5):717–24.  
46  
47  
48 16. Roy KM, Hutchinson SJ, Wadd S, Taylor A, Cameron SO, Burns S, et al. Hepatitis C virus  
49  
50 infection among injecting drug users in Scotland: a review of prevalence and incidence data  
51  
52 and the methods used to generate them. *Epidemiol Infect.* 2007;135(3):433–42.  
53  
54  
55 17. Knapp S, Warshow UM, Hegazy D, Brackenbury L, Guha IN, Fowell A, et al. Consistent  
56  
57 beneficial effects of killer cell immunoglobulin-like receptor 2d13 and group 1 human  
58  
59 leukocyte antigen-c following exposure to hepatitis c virus. *Hepatology.* 2010 Apr;51(4):1168–  
60

- 1  
2  
3 75.  
4  
5  
6 18. Sugden PB, Cameron B, Luciani F, Lloyd AR. Exploration of genetically determined resistance  
7 against hepatitis C infection in high-risk injecting drug users. *J Viral Hepat.* 2014;21(8):36–41.  
8  
9  
10 19. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-  
11 linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. *J*  
12 *Immunol Methods.* 1983;65(1–2):109–21.  
13  
14  
15 20. MABTECH. ELISpot [Internet]. <https://www.mabtech.com>. 2016 [cited 2016 Dec 12]. Available  
16 from: <https://www.mabtech.com/sites/default/files/2013-elispot-web.pdf>  
17  
18  
19 21. Gremion C, Cerny A, Heim MH, Huckans M, Fuller BE, Olavarria H, et al. Viral and  
20 immunological determinants of hepatitis C virus clearance, persistence, and disease. *J Gen*  
21 *Virol.* 2002;99(3):235–68.  
22  
23  
24 22. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari F V. Determinants of viral clearance  
25 and persistence during acute hepatitis C virus infection. *J Exp Med.* 2001;194(10):1395–406.  
26  
27  
28 23. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.  
29 *Nat Med.* Nature Publishing Group; 2013;19(7):859–68.  
30  
31  
32 24. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus  
33 infection. *Nature.* 2005;436(7053):946–52.  
34  
35  
36 25. Garten R-J, Lai S-H, Zhang J-B, Liu W, Chen J, Yu X-F. Factors influencing a low rate of hepatitis  
37 C viral RNA clearance in heroin users from Southern China. *World J Gastroenterol.*  
38 2008;14(12):1878–84.  
39  
40  
41 26. Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with  
42 spontaneous clearance of hepatitis C virus among illicit drug users. *Can J Gastroenterol.*  
43 2007;21(7):447–51.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57 27. The European Association for the Study of the Liver. EASL recommendations on treatment of  
58  
59  
60

- 1  
2  
3 hepatitis C 2014. *J Hepatol. European Association for the Study of the Liver*; 2014;61(2):373–  
4  
5 95.  
6  
7  
8 28. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in  
9  
10 injection drug users. *Hepatology*. 2006;44(5):1139–45.  
11  
12 29. Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R, et al. Hepatitis C virus (HCV)  
13  
14 specific immune responses in anti-HCV positive patients without hepatitis C viraemia. *Gut*.  
15  
16 1999;44(3).  
17  
18 30. Thuraiajah PH, Hegazy D, Demaine A, Kaminski ER, Cramp ME. Loss of virus-specific T-cell  
19  
20 responses in HCV exposed uninfected injection drug users with drug rehabilitation. *J Infect Dis*.  
21  
22 2011 Mar 15;203(6):847–53.  
23  
24  
25 31. Mina MM, Luciani F, Cameron B, Bull R a, Beard MR, Booth D, et al. Resistance to hepatitis C  
26  
27 virus: potential genetic and immunological determinants. *Lancet Infect Dis. Elsevier Ltd*;  
28  
29 2015;15(4):451–60.  
30  
31  
32 32. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, et al. Presence of  
33  
34 effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. *J Immunol*.  
35  
36 1999;162(11):6681–9.  
37  
38  
39 33. Al-Sherbiny M, Osman A, Mohamed N, Shata MT, Abdel-Aziz F, Abdel-Hamid M, et al.  
40  
41 Exposure to hepatitis C virus induces cellular immune responses without detectable viremia  
42  
43 or seroconversion. *Am J Trop Med Hyg*. 2005;73(1):44–9.  
44  
45  
46 34. Heller T, Werner JM, Rahman F, Mizukoshi E, Sobao Y, Gordon AM, et al. Occupational  
47  
48 exposure to hepatitis C virus: Early T-cell responses in the absence of seroconversion in a  
49  
50 longitudinal cohort study. *J Infect Dis*. 2013;208(6):1020–5.  
51  
52  
53 35. Park S, Veerapu NS, Shin E, Biancotto A, McCoy JP, Capone S, et al. Subinfectious hepatitis C  
54  
55 virus exposures suppress T cell responses against subsequent acute infection. *Nat Med*.  
56  
57 2013;19(12):1638–42.  
58  
59  
60

- 1  
2  
3 36. Sugden PB, Cameron B, Mina M, Lloyd AR. Protection against hepatitis C infection via NK cells  
4  
5 in highly-exposed uninfected injecting drug users. *J Hepatol.* 2013;61(4):738–45.  
6
- 7  
8 37. Post JJ, Pan Y, Freeman AJ, Harvey CE, White P a, Palladinetti P, et al. Clearance of hepatitis C  
9  
10 viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C  
11  
12 incidence and transmission in prisons study cohort. *J Infect Dis.* 2004;189(10):1846–55.  
13
- 14  
15 38. Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, et al. Clearance of low  
16  
17 levels of HCV viremia in the absence of a strong adaptive immune response. *Virology.* 2007;4:58.  
18
- 19  
20 39. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous Control of Primary  
21  
22 Hepatitis C Virus Infection and Immunity Against Persistent Reinfection. *Gastroenterology.*  
23  
24 2010;138(1):315–24.  
25
- 26  
27 40. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, et al. Clearance of Hepatitis  
28  
29 C infection is associated with early appearance of broad neutralizing antibody responses.  
30  
31 *Hepatology.* 2014;59(6):1–12.  
32
- 33  
34 41. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous  
35  
36 clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing  
37  
38 antibodies and reversal of T-cell exhaustion. *J Infect Dis.* Oxford University Press; 2012 Mar  
39  
40 1;205(5):763–71.  
41
- 42  
43 42. de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, Robbins JB, et al. Broadly  
44  
45 neutralizing antibodies abrogate established hepatitis C virus infection. *Sci Transl Med.* NIH  
46  
47 Public Access; 2014 Sep 17;6(254):254ra129.  
48
- 49  
50 43. Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, et al. Effect of  
51  
52 immune globulin on the prevention of experimental hepatitis C virus infection. *J Infect Dis.*  
53  
54 1996;173(4):822–8.  
55
- 56  
57 44. Swann RE, Mandalou P, Robinson MW, Ow MM, Fong SKH, Mclauchlan J, et al. Anti-  
58  
59 envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.  
60

- Journal of Viral Hepatitis. 2016 Jul;1–8.
45. Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE, et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. *J Immunol.* 1999;163:2314–21.
46. Warshow UM, Riva a., Hegazy D, Thurairajah PH, Kaminski ER, Chokshi S, et al. Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection. *J Viral Hepat.* 2012;19(7):501–8.
47. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. *Science* (80- ). 2004;305(5685):872–4.
48. Knapp S, Warshow U, Ho KMA, Hegazy D, Little A-M, Fowell A, et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. *Gastroenterology.* 2011 Jul;141(1):320–5, 325-2.
49. Thoens C, Berger C, Trippler M, Siemann H, Lutterbeck M, Broering R, et al. KIR2DL3+NKG2A– natural killer cells are associated with protection from productive hepatitis C virus infection in people who inject drugs. *J Hepatol.* 2014;61(3):475–81.
50. Hegazy D, Thurairajah P, Metzner M, Houldsworth a., Shaw S, Kaminski E, et al. Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection. *Clin Exp Immunol.* 2008 Jun;152(3):538–41.
51. Seegers D, Zwiers a, Strober W, Peña a S, Bouma G. A TaqI polymorphism in the 3'UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. *Genes Immun.* 2002;3(7):419–23.
52. Zhu Y-Z, Qian X-J, Zhao P, Qi Z-T. How hepatitis C virus invades hepatocytes: The mystery of viral entry. *World J Gastroenterol.* 2014 Apr 7;20(13):3457–67.

- 1  
2  
3 53. Houldsworth A, Metzner MM, Demaine A, Hodgkinson A, Kaminski E, Cramp M. CD81  
4  
5 sequence and susceptibility to hepatitis C infection. *J Med Virol.* 2014;86(1):162–8.  
6  
7  
8 54. Ghosn J, Fouquet B, Quertainmont Y, Salmon D, Sahali S, Rioux C, et al. Claudin-1 gene  
9  
10 variants and susceptibility to hepatitis C infection in HIV-1 infected intravenous drug users (an  
11  
12 ANRS case-control study). *J Med Virol.* 2015 Apr;87(4):619–24.  
13  
14 55. Fouquet B, Ghosn J, Quertainmont Y, Salmon D, Rioux C, Duvivier C, et al. Identification of  
15  
16 Variants of Hepatitis C Virus (HCV) Entry Factors in Patients Highly Exposed to HCV but  
17  
18 Remaining Uninfected: An ANRS Case-Control Study. *PLoS One.* 2015;10(11):e0142698.  
19  
20  
21 56. Fénéant L, Ghosn J, Fouquet B, Helle F, Belouzard S, Vausselin T, et al. Claudin-6 and Occludin  
22  
23 Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus  
24  
25 (HCV) Do Not Confer HCV Resistance In Vitro. Ray RB, editor. *PLoS One.* 2015 Nov  
26  
27 12;10(11):e0142539.  
28  
29  
30 57. Piver E, Roingeard P, Pagès J-C. The cell biology of hepatitis C virus (HCV) lipid addiction:  
31  
32 molecular mechanisms and its potential importance in the clinic. *Int J Biochem Cell Biol.* 2010  
33  
34 Jun;42(6):869–79.  
35  
36  
37 58. Diaz O, Delers F, Maynard M, Demignot S, Zoulim F, Chambaz J, et al. Preferential association  
38  
39 of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. *J Gen Virol.*  
40  
41 2006;87(10):2983–91.  
42  
43  
44 59. Fauvelle C, Felmler DJ, Crouch E, Lee J, Heydmann L, Lefèvre M, et al. Apolipoprotein e  
45  
46 Mediates Evasion from Hepatitis C Virus Neutralizing Antibodies. *Gastroenterology.*  
47  
48 2016;150(1):206–217.e4.  
49  
50  
51 60. Bassendine MF, Sheridan D a, Felmler DJ, Bridge SH, Toms GL, Neely RDG. HCV and the  
52  
53 hepatic lipid pathway as a potential treatment target. *J Hepatol. European Association for the*  
54  
55 *Study of the Liver;* 2011 Dec;55(6):1428–40.  
56  
57  
58 61. Shawa IT, Gomez-Romero M, Pechlivanis A, Felmler DJ, Crossey M, Holmes E, et al. Serum  
59  
60

lipid profiling using Ultra-performance liquid chromatography mass spectrometry (UPLC/MS) discriminates HCV exposed uninfected injection drug users from those susceptible to infection. In: British Association for the study of the Liver (BASL) Annual Meeting. Manchester: <http://www.baslannualmeeting.org.uk/>; 2016.

62. Mandalou P, Swann R, Patel AH, Cramp ME. Poster: HCV Virology, Pathogenesis, and Immunology. In: Hepatology. 2014. p. 1048A–1087A.
63. Tawar RG, Colpitts CC, Timm J, Fehm T, Roggendorf M, Meisel H, et al. Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties. Hepatology. 2015 Sep;62(3):726–36.
64. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity. Elsevier Inc.; 2014;40(1):13–24.

## Tables

Immunological and genetic differences based on HCV natural history

	<b>Exposed Uninfected</b>	<b>Spontaneous resolution</b>	<b>Chronic Infection</b>
<b>Anti- HCV</b>	Persistently negative	positive	positive
<b>HCV RNA</b>	Persistently not detected	Transient positive, then persistently negative	Two positive > 6 months apart
<b>Neutralising antibody responses</b>	Detected in 27% (62)	Associated with early development of broadly neutralising antibody responses (40).  And anti-host receptor (CD81) antibodies (63).	Readily detectable neutralising antibodies in chronic infection
<b>T cell responses</b>	Detected in 60% but weak and wane on cessation of HCV exposure (17)	Early vigorous and broad anti HCV T cell responses typical (23).	Initial T-cell responses weaken. Loss of CD4 T-cell help, switch to a T-reg cell profile, viral epitope escape, chronic antigen stimulation contribute to T-cell exhaustion (64).
<b>Genetic factors</b>	↑ KIR2DL3 HLA-C (17).  Not IFNλ3 (48)	↑ KIR2DL3 HLA-C (17)  IFLλ3 CC (48)	↓ KIR2DL3 HLA-C (17).  IFNλ3 (48)